Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- D-dimer
研究概览
简要总结
Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia
详细描述
This is a randomized clinical trial study that will be carried out on 100 children with Community-acquired pneumonia admitted to the Pulmonology Unit, Pediatric department.
Group 1: Pentoxifylline group, and group 2: Control group
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 2 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia
排除标准
- •Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with CHD affecting the pulmonary blood flow.
研究组 & 干预措施
50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form
50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form at a dose of 20 mg/kg/day, as an adjunct therapy to the usual pneumonia treatment for 5 days
干预措施: Pentoxifylline Oral Tablet (Drug)
结局指标
主要结局
D-dimer
时间窗: 5 days
Duration of normalization of D-dimer
Interleukin 6
时间窗: 5 days
Duration of normalization of IL-6
Oxygen saturation
时间窗: 3 days
Duration of normalization of hypoxia
Respiratory distress
时间窗: 3 days
Duration of improvement of respiratory distress
CRP
时间窗: 5 days
Duration of normalization of CRP
LDH
时间窗: 5 days
Duration of normalization of LDH
Temperature
时间窗: 3 days
Duration of defeverness
次要结局
- Hospital stays(14 days)
- Pneumonia complications(14 days)
研究者
Rehab Zaki Elmeazawy
Doctor
Tanta University